Drug Combination Details
| General Information of the Combination (ID: C93664) | |||||
|---|---|---|---|---|---|
| Name | Daidzein NP Info | + | Topotecan Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | Adult female athymic nude mice (six-week-old) were injected with MCF7 cells (5*106 cells/mouse) to construct subcutaneous breast cancer xenografts. | |||||
| Experimental
Result(s) |
Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019 Sep;147:104387. | |||
